- Home
- / Y-mAbs Therapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Y-mAbs Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$14.7
2024-10-29
Market Capitalization
$657 M
2024-10-29
Revenue
$87.7 M
FY, 2024
CreditSafe Score
?
Score changed on Jun 08, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 20.8M | 34.9M | 65.3M | 84.8M | 87.7M | ||||
| Cost of goods sold | 2.3M | 7.5M | 11.4M | 15.0M | |||||
| Gross profit | 57.8M | 73.5M | 72.7M | ||||||
| Gross profit margin, % | 88.6% | 86.6% | 82.9% | ||||||
| General and administrative expense | 3.2M | 4.9M | 9.0M | 19.5M | 44.8M | 54.6M | 60.9M | 44.9M | 54.6M |
| Operating expense total | 17.0M | 19.2M | 43.2M | 83.0M | 44.8M | 148.0M | 152.6M | 99.1M | 103.9M |
| EBIT | (17.0M) | (19.2M) | (43.2M) | (83.0M) | (119.9M) | (115.4M) | (94.8M) | (25.7M) | (31.2M) |
| EBIT margin, % | -576.6% | -145.3% | -30.3% | -35.6% | |||||
| Pre tax profit | (43.3M) | (81.0M) | (119.3M) | (55.3M) | (95.6M) | (20.9M) | (29.8M) | ||
| Income tax expense | 561.0K | (146.0K) | |||||||
| Net Income | (17.0M) | (19.4M) | (43.3M) | (81.0M) | (119.3M) | (55.3M) | (95.6M) | (21.4M) | (29.7M) |
| EPS | (2.2) | (0.5) | (0.7) |